ATLANTA, June 23 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biopharmaceutical company developing human vaccines for diseases caused by the HIV-1 (Human Immunodeficiency Virus), and other infectious agents, today announced the results of its Annual Shareholders Meeting, held on June 18, 2009.
During the meeting, shareholders re-elected seven nominees for directors of the company to serve until the 2010 Annual Meeting of Shareholders and until their successors are duly elected or appointed and qualified. They are: Donald Hildebrand, Andrew Kandalepas, Dean Kollintzas, Robert McNally, Harriet Robinson, John Spencer and Peter Tsolinas. Additionally, stockholders ratified the appointment of Porter Keadle Moore LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2009.
Don Hildebrand, company co-founder and Chairman of the Board of Directors, provided opening remarks at the meeting, highlighting significant progress over the past year. A few of the key advances presented included: GeoVax as being the only company currently conducting Phase 2a clinical trials for an AIDS vaccine in the U.S., excellent safety and immune responses being reported in five completed human trials, the advancement of plans to begin human therapeutic [treatment] trials in the U.S., stable corporate financial condition, rising recent stock price, substantial increase in the number of new investors in GeoVax, substantial press coverage and investor interest at the World BIO Conference in Atlanta, invitations to present GeoVax at various investor conferences and several scientific presentations and publications by Dr. Robinson in the U.S. as well as in Europe.
In addition to the business of the annual meeting, Robert McNally, president and chief executive officer, provided an overview of the company's progress, highlighting GeoVax's
|SOURCE GeoVax Labs, Inc.|
Copyright©2009 PR Newswire.
All rights reserved